▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Cara Therapeutics (NASDAQ: CARA)

Some price data may be temporarily unavailable.

Cara Therapeutics Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
CARA	-2.98%	-95.45%	-46.10%	-97%
S&P	+11.91%	+101.47%	+15.04%	+233%

Cara Therapeutics Company Info

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

News & Analysis

The Fool has written over 200 articles on Cara Therapeutics.

Featured Article

Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval

There's good news at long last for the beaten-down biotech stock.

Keith Speights and Brian Orelli, PhD | Sep 4, 2021

Featured Article

Why Cara Therapeutics Shot Higher Today

The biotech gets an important nod from a top regulator.

Eric Volkman | Aug 24, 2021

Is Cara Therapeutics a Buy for Summer 2021?

Zhiyuan Sun | May 29, 2021

The future of this troubled clinical-stage biotech rests on a single drug candidate that management hopes will treat an extremely common condition.

Is Cara Therapeutics a Buy?

Alex Carchidi | May 23, 2021

Maybe, if you're itching to speculate.

Why Cara Therapeutics Stock Is Crashing Today

Keith Speights | Apr 29, 2021

The company reported disappointing results from a phase 2 study.

Why Cara Therapeutics Stock Is Soaring Higher Today

Keith Speights | Apr 6, 2021

The biotech stock is being added to an important small-cap index.

Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

Keith Speights | Jun 28, 2020

Both of these biotechs could have big catalysts on the way.

3 Pot Stocks Worth a Second Look

Jim Halley | Jun 26, 2020

These companies are all surprising doubters lately.

Valuation

Podcast Episodes

Can Drugmakers Cure the Opioid Crisis?

Deaths from prescription opioids have quadrupled since 1999, but new drugs that reduce their use may help end the opioid epidemic.

Todd Campbell and Kristine Harjes | Apr 18, 2017

Earnings Transcripts

Cara Therapeutics, inc (CARA) Q3 2021 Earnings Call Transcript

CARA earnings call for the period ending September 30, 2021.

Motley Fool Transcribers | Nov 8, 2021

Cara Therapeutics, inc (CARA) Q2 2021 Earnings Call Transcript

CARA earnings call for the period ending June 30, 2021.

Motley Fool Transcribers | Aug 9, 2021

Cara Therapeutics Inc (CARA) Q1 2021 Earnings Call Transcript

CARA earnings call for the period ending March 31, 2021.

Motley Fool Transcribers | May 10, 2021

Cara Therapeutics Inc (CARA) Q4 2020 Earnings Call Transcript

CARA earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Feb 26, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services